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Abstract: Mice lacking the core-clock components, cryptochrome-1 (CRY1) and cryptochrome-2
(CRY2) display a phenotype of hyperaldosteronism, due to the upregulation of type VI
3β-hydroxyl-steroid dehydrogenase (Hsd3b6), the murine counterpart to the human type I
3β-hydroxyl-steroid dehydrogenase (HSD3B1) gene. In the present study, we evaluated the role of
CRY1 and CRY2 genes, and their potential interplay with HSD3B isoforms in adrenal pathophysiology
in man. Forty-six sporadic aldosterone-producing adenomas (APAs) and 20 paired adrenal samples
were included, with the human adrenocortical cells HAC15 used as the in vitro model. In our cohort
of sporadic APAs, CRY1 expression was 1.7-fold [0.75–2.26] higher (p = 0.016), while CRY2 showed a
20% lower expression [0.80, 0.52–1.08] (p = 0.04) in APAs when compared with the corresponding
adjacent adrenal cortex. Type II 3β-hydroxyl-steroid dehydrogenase (HSD3B2) was 317-fold [200–573]
more expressed than HSD3B1, and is the main HSD3B isoform in APAs. Both dehydrogenases
were more expressed in APAs when compared with the adjacent cortex (5.7-fold and 3.5-fold,
respectively, p < 0.001 and p = 0.001) and HSD3B1 was significantly more expressed in APAs
composed mainly of zona glomerulosa-like cells. Treatment with angiotensin II (AngII) resulted in
a significant upregulation of CRY1 (1.7 ± 0.25-fold, p < 0.001) at 6 h, and downregulation of CRY2
at 12 h (0.6 ± 0.1-fold, p < 0.001), through activation of the AngII type 1 receptor. Independent
silencing of CRY1 and CRY2 genes in HAC15 cells resulted in a mild upregulation of HSD3B2 without
affecting HSD3B1 expression. In conclusion, our results support the hypothesis that CRY1 and CRY2,
being AngII-regulated genes, and showing a differential expression in APAs when compared with
the adjacent adrenal cortex, might be involved in adrenal cell function, and in the regulation of
aldosterone production.
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1. Introduction
Primary aldosteronism (PA), affecting 6% of the general hypertensive population [1], and up
to 20% of patients referred to hypertension units [2,3], is widely recognized as the leading cause of
endocrine hypertension. Aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia
(BAH) are the most frequent underlying causes of PA, while unilateral adrenal hyperplasia (UAH)
is less common. The last few years witnessed major advances in the understanding of the
molecular determinants leading to autonomous aldosterone overproduction in both sporadic and
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familial PA. In particular, the introduction of next-generation sequencing allowed the identification
of somatic mutations in four genes differently involved in Ca2+ homeostasis (KCNJ5, ATP1A1,
ATP2B3, and CACNA1D), unraveling the genetic basis of approximately 50% of sporadic APAs [4–7].
Similarly, new insight was gained from mice lacking the core-clock components, cryptochrome-1
(CRY1) and cryptochrome-2 (CRY2) (Cry-null mice) [8]. Mammals, as well as many other organisms
including plants, adapt most of their physiologic processes to a 24-h time cycle, generated by an internal
molecular oscillator referred to as the circadian clock [9]. At the cellular level, circadian oscillations are
generated by a series of genes, whose proteic products form a transcriptional autoregulatory feedback
loop, where clock circadian regulator (CLOCK) and aryl hydrocarbon receptor nuclear translocator-like
protein 1 (ARNTL, also known as BMAL1) act as positive regulators, while period (PER) and CRY
act as negative regulators [10]. Cry-null mice displayed salt-sensitive hypertension due to chronic
and autonomous aldosterone overproduction by the adrenal glands, as a consequence of the massive
upregulation of type VI 3β-hydroxyl-steroid dehydrogenase (Hsd3b6), the murine counterpart to the
human type I 3β-hydroxyl-steroid dehydrogenase (HSD3B1) gene [8]. HSD3B catalyzes the conversion
of pregnenolone to progesterone, an enzymatic reaction required for aldosterone biosynthesis [11];
two different HSD3B isoforms are expressed in man—HSD3B1 is mainly expressed in the placenta,
while HSD3B2 localizes primarily in adrenals and gonads [12]. Immunohistochemistry studies in
normal human adrenals showed that HSD3B2 is the predominant isoform, expressed through the
zona glomerulosa and the zona fasciculata (ZF), while HSD3B1 displays faint immunoreactivity,
predominantly in the outermost layer zona glomerulosa (ZG) [8,13,14]. Moreover, in APA samples,
HSD3B1 expression was significantly correlated with the expression of the rate-limiting enzyme for
aldosterone production—aldosterone synthase (CYP11B2) [15]. Despite much knowledge being gained
from the Cry-null animal model, the significance of CRY1 and CRY2 in human adrenal function and
aldosterone production is still unknown. So far, few reports have investigated the roles of HSD3B1 and
HSD3B2 in sporadic PA. Therefore, in this study we aimed to (I) evaluate the expressions of HSD3B1
and HSD3B2 in a large cohort of 46 adrenal glands, removed from patients in whom a final diagnosis
of unilateral PA was achieved; and (II) investigate the expression of CRY1 and CRY2 in unilateral
sporadic PA, and their roles in aldosterone production in the HAC15 human adrenocortical cell model.
2. Results
2.1. Expression of CRY1, CRY2, HSD3B1, and HSD3B2 in Adrenal Tissues
The expression levels of CRY1, CRY2, HSD3B1, and HSD3B2 were determined by real-time
PCR in a cohort of 46 sporadic APAs, and 20 paired adjacent adrenal tissues. Within the same
sample, the median expression of CRY1 was 2.1-fold [1.45–2.87] higher than that of CRY2, consistently
in both APA and UAH (Figure 1A). In our cohort, the expression of both CRY genes was neither
associated with the cellular composition of the APAs (CRY1 expression in ZG-like APAs: 1.46
[0.45–2.59], CRY1 expression in ZF-like APAs: 0.96 [0.49–1.58], p-value 0.291; CRY2 expression in
ZG-like APAs: 1.24 [0.57–2.05], CRY2 expression in ZF-like APAs: 0.84 [0.62–1.28], p-value 0.170) nor
with the mutational status (CRY1 expression in wild-type APAs: 1.39 [0.58–2.7], CRY1 expression
in KCNJ5 mutant APAs: 0.89 [0.42–1.70], CRY1 expression in ATP1A1-ATP2B3 mutant APAs: 0.89
[0.49–1.09], CRY1 expression in CACNA1D mutant APAs: 1.4 [0.64–2.61], p-value = 0.417; CRY2
expression in wild-type APAs: 1.08 [0.61–1.98], CRY2 expression in KCNJ5 mutant APAs: 0.98
[0.54–1.41], CRY2 expression in ATP1A1-ATP2B3 mutant APAs: 0.89 [0.62–1.06], CRY2 expression in
CACNA1D mutant APAs: 1.61 [0.80–2.87], p-value = 0.170). While the median expression of CRY1
was 1.7-fold [0.75–2.26] higher in APA tissues when compared with that in the adjacent adrenal cortex
(p = 0.016), CRY2 showed a 20% lower expression [0.80, 0.52–1.08] in the nodule when compared with
the corresponding surrounding tissue (p = 0.04) (Figure 1B). Representative immunohistochemistry
staining of frozen tissue sections showing the expression of CRY1 and CRY2 in APA and adjacent
adrenal cortex is illustrated in Figure 2A–F.
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In both APA and UAH samples, HSD3B2 was the main isoform, with an overall median expression
317-fold [200–573] higher than that of HSD3B1 (p < 0.001) (Figure 1C). HSD3B1 transcription was
significantly more abundant (median fold change 5.2, p < 0.001) in APAs that were composed mainly
of ZG-like cells when compared with APAs that had a ZF-like morphology (Figure 1D). A tendency
towards a higher HSD3B2 expression in APAs composed mainly of ZG-like cells was observed,
but the difference did not reach statistical significance (median fold change 1.8, p = 0.051) (Figure 1E).
In addition, the median HSD3B1/HSD3B2 relative ratio was 1.9-fold higher in APA samples composed
mainly of ZG-like cells (p = 0.003) when compared with APAs composed mainly of ZF-like cells
(Figure 1F). No differences in the expression of HSD3B1 or HSD3B2, according to the mutational
status (HSD3B1 expression in wild-type APAs: 1.37 [0.42–4.5], HSD3B1 expression in KCNJ5 mutant
APAs: 0.51 [0.30–1.97], HSD3B1 expression in ATP1A1-ATP2B3 mutant APAs: 0.66 [0.27–1.63], HSD3B1
expression in CACNA1D mutant APAs: 2.27 [1.40–3.12], p-value = 0.212; HSD3B2 expression in
wild-type APAs: 1.0 [0.75–2.37], HSD3B2 expression in KCNJ5 mutant APAs: 1.01 [0.68–2.18], HSD3B2
expression in ATP1A1-ATP2B3 mutant APAs: 0.69 [0.46–0.93], HSD3B2 expression in CACNA1D
mutant APAs: 2.82 [1.16–3.19], p-value = 0.147) or the final diagnosis (HSD3B1 expression in APAs:
1.37 [0.30–3.00], HSD3B1 expression in UAHs: 0.66 [0.42–3.61], p-value 0.899; HSD3B2 expression in
APAs: 1.17 [0.66–2.63], HSD3B2 expression in UAHs: 0.99 [0.71–1.63], p-value 0.523), were observed.
Notably, both HSD3B1 and HSD3B2 were significantly more expressed in the main nodule when
compared with adjacent adrenal tissue (5.7- and 3.5-fold, respectively, p < 0.001 and p = 0.001)
(Figure 1G). Representative immunohistochemistry staining of frozen tissue sections showing the
expression of HSD3B1 and HSD3B2 in APAs, according to the cellular composition, is illustrated in
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Figure 1. (A) Relative quantification of cryptochrome-1 (CRY1) mRNA over cryptochrome-2 (CRY2)
messenger RNA (mRNA) in the total cohort, in aldosterone-producing adenoma (APA) samples (n = 35)
and in unilateral adrenal hyperplasia (UAH) samples (n = 11). (B) Relative quantification of CRY1
and CRY2 mRNA in APA samples over that in the corresponding adjacent adrenal cortex (n = 20).
(C) Relative quantification of type II 3β-hydroxyl-steroid dehydrogenase (HSD3B2) mRNA over type I
3β-hydroxyl-steroid dehydrogenase (HSD3B1) mRNA in the total cohort, in APA samples (n = 35) and
in UAH samples (n = 11). (D) HSD3B1 mRNA expression according to the cellular composition in the
total cohort of adrenal samples. (E) HSD3B2 mRNA expression according to the cellular composition
in the total cohort of adrenal samples. (F) Relative quantification of HSD3B1 mRNA over HSD3B2
mRNA according to the cellular composition. (G) Relative quantification of HSD3B1 and HSD3B2
mRNA in APA samples over that in the corresponding adjacent adrenal cortex. For each box plot,
the horizontal line represents the median, and the box and bar indicate the 25th to 75th and 5th to 95th
percentiles, respectively.
2.2. Regulation of CRY1, CRY2, HSD3B1, and HSD3B2 Expression in HAC15 Cells
To investigate the potential roles of CRY1 and CRY2 genes in adrenal cell function and aldosterone
production, we used HAC15 adrenocortical cells as an in vitro model. CRY1 and CRY2 genes were
transcribed in HAC15 cells to a level comparable to that of a pooled set of APA samples, while HSD3B2
was 35-fold (25–61, p < 0.001) more expressed than HSD3B1.
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Figure 2. (A–C) Representative immunohistochemistry staining for CRY1 in APAs. (D–F) Representative
immunohistochemistry staining for CRY2 in APAs. Magnifications in (B,C), and in (E,F) correspond to
the boxed sections in (A,D), respectively.
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HAC15 cells, which were previously reported to express the AngII type 1 receptor [16],
were stimulated with AngII (±1 µM irbesartan) or forskolin for 6, 12, and 24 h, and were then
harvested for RNA extraction and gene-expression studies.
As expected, treatment with AngII (100 nM) resulted in a significant increase in CYP11B2
expression at 12 h (68 ± 20-fold over basal, p < 0.001).
Treatment with AngII significantly increased the expression of CRY1 mRNA within 6 h
(1.7 ± 0.25-fold, p < 0.001). Following a peak in expression, the levels of CRY1 mRNA returned
to basal levels after 12 h of AngII treatment (Figure 4A). With respect to CRY2 expression, stimulation
with AngII resulted in a significant downregulation (0.6 ± 0.1-fold, p < 0.001) at 12 h (Figure 4B),
followed by a return to basal levels at 24 h.
Treatment with forskolin, which mimics adrenocorticotropin (ACTH)-mediated elevation of
intracellular cyclic adenosine monophosphate (cAMP), resulted in a downregulation of CRY1 at 6, 12,
and 24 h, and a downregulation of CRY2 and at 12 and 24 h (Figure 4A,B).
Additionally, AngII and forskolin treatment positively regulated the transcription of both HSD3B1
and HSD3B2. Following a 6-h stimulation with AngII, we observed that HSD3B1 was 3.2 ± 2.4-fold
(p = 0.035) more expressed when compared with basal conditions, while the maximum upregulation of
HSD3B2 was observed at 12 h (3.7 ± 0.4-fold, p = 0.002) (Figure 4C,D). Similarly, forskolin treatment
induced a significant upregulation of both HSD3B1, with a peak at 6 h, and HSD3B2, with a peak at
12 h, (2.1 ± 1.2-fold and 5.1 ± 2.1-fold, p = 0.03 and p = 0.001, respectively).
Consistently, after 6 h of AngII stimulation, we detected a 1.5 ± 0.2-fold upregulation of PER1,
that acts as a negative regulator of the core clock together with CRY, followed by a 42% reduction at
12 h, when compared with basal levels (Figure 4E).
Pre-treatment with irbersartan (1 µM) reverted the effects of AngII on PER1, CRY1, and CRY2
expression (Figure 4F–H), indicating that the observed effects on gene expression were mediated by
the activation of the AngII type 1 receptor.
2.3. Effect of CRY1 and CRY2 Silencing in HAC15 Cells
Our observation of the regulation of CRY genes by AngII, together with the experimental evidence
available from Cry-null mice [8], prompted us to investigate the effect of CRY silencing on gene
expression in HAC15 cells.
Silencing CRY genes by transfection of siRNA resulted in a 62% reduction in CRY1 mRNA
levels, and a 70% reduction in CRY2 mRNA levels, measured by real-time PCR (Figure 5A,B).
Notably, silencing CRY1 induced a significant upregulation of CRY2 (1.3 ± 0.2-fold, p = 0.005)
(Figure 5B), which resulted in less efficient CRY2 silencing when the double CRY1 and CRY2 siRNA
assay was performed, for this reason simultaneous silencing of both genes was not allowed.
The expression of mRNA-encoding key enzymes involved in the production of aldosterone was
examined. Transfection with CRY1 siRNA resulted in a significant upregulation of HSD3B2 expression
(1.30± 0.23-fold, p = 0.009) (Figure 5F), and a trend toward the upregulation of HSD3B1 (1.20± 0.5-fold,
p = not significant) (Figure 5E), while the transfection with CRY2 siRNA did not affect the expression
of either HSD3B1 or HSD3B2. Similarly, the expression of CYP11B2, and its main transcriptional
factor NR4A2 were not significantly modified at the evaluated timepoint (42 h post-transfection)
(Figure 5C,D).
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might represent the molecular mechanism responsible for autonomous aldosterone overproduction in
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So far, the role and clinical significance of CRY1 and CRY2 genes in the regulation of aldosterone
production and APA development, together with their potential interplay with HSD3B isoforms,
were not explored in humans.
In this study, we demonstrated, for the first time, that CRY1 is overexpressed, while CRY2
is downregulated in APA tissue, when compared with the paired adjacent adrenal cortex,
which represents the optimal control tissue, given the multiplicity of factors that influence the
transcription of the core-clock genes [9]. In agreement with previous reports [15], we observed
that HSD3B2, being over 300-fold more expressed than HSD3B1, is the principal isoform in APAs.
A previous study showed that HSD3B1 (evaluated as H-score) was more expressed in APAs
carrying somatic mutations in the KCNJ5 gene [15], while in our cohort we did not detect any
significant association between the expression of HSD3B1 (evaluated by real-time PCR) and the
mutational status of the samples. On the contrary, we observed that both HSD3B1 expression and
the relative HSD3B1/HSD3B2 ratio were significantly more elevated in APAs composed mainly of
zona glomerulosa-like cells (while APAs carrying a mutation in KCNJ5 are composed mainly of zona
fasciculata-like cells [20]).
Additionally, this study demonstrated, for the first time, that the expression of both CRY1 and
CRY2 genes is modulated by AngII through activation of the AT1R. Similarly, the negative regulator
PER1 showed an AngII-dependent regulation. It was previously reported that stimulation with AngII
for three hours induced the negative regulator of the core-clock protein PER1 in H295R adrenocortical
cells [21]. Additionally, overexpressing PER1 in H295R cells was able to induce CYP11B1 and CYP11B2
promoter activity [21]. A role for the circadian-clock protein PER1 in the regulation of aldosterone
production was recently reported in both in vitro and in vivo studies. Per1 knock-out mice displayed
lower aldosterone levels when compared with wild-type animals, and also a lower expression of
Hsd3b6 in adrenal gland tissue [22]. Silencing PER1 in H295R cells was able to decrease the expression
of HSD3B1 isoform by 58%, supporting the hypothesis that PER1 is involved in the modulation of
serum aldosterone levels [22].
In the presented study, we showed that AngII stimulation triggers the expression of both HSD3B1
and HSD3B2 in HAC15 cells; our results differ from those reported by Ota T. et al. [23], showing that
AngII can induce the expression of HSD3B1, but not HSD3B2 in H295R cells.
To further investigate the potential role of CRY1 and CRY2 in the regulation of HD3B isoforms,
we transfected HAC15 cells with CRY1 and CRY2 siRNA. Contrary to what was expected from the
Cry-null and the Per knock-out murine models, silencing CRY genes did not modify the expression
of HSD3B1; however, we observed a mild upregulation of HSD3B2 in HAC15 cells transfected
with CRY1 siRNA. However, as previously described [24], silencing CRY1 resulted in a significant
upregulation of CRY2, which did not allow us to perform an efficient double silencing, and could,
therefore, have affected the results, representing a limitation of the presented study.
4. Materials and Methods
4.1. Patients Selection
A total of 46 adrenal adenomas and 20 paired adjacent adrenal samples were included in the
presented study. The adrenal glands were removed from patients affected by unilateral PA, diagnosed
in our tertiary referral hypertension centre (Division of Internal Medicine 4—Hypertension Unit,
at the University of Torino, Italy). The diagnostic work-up for PA was performed according to
the recommendations of the Endocrine Society clinical practice guideline [25]. After withdrawal of
interfering medications, the ratio of aldosterone to plasma renin activity was used as a screening
test for PA. To confirm the diagnosis, either an intravenous (i.v.) saline load test or a captopril
challenge test (when acute plasma volume expansion was contraindicated) was performed. All patients
with confirmed PA underwent adrenal computed tomography (CT) scanning and adrenal vein
sampling (AVS), as previously described [26]. All patients showing lateralization upon AVS underwent
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unilateral laparoscopic adrenalectomy. The diagnosis of unilateral PA was confirmed based on clinical
benefit and a complete biochemical outcome after adrenalectomy, as defined according to a recent
consensus (Primary Aldosteronism Surgical Outcome, PASO) [27]. Clinical and biochemical parameters
(before and after adrenalectomy) of the included patients are summarized in Table S1. Normal adrenal
glands were obtained from normotensive patients who underwent unilateral nephrectomy for renal
carcinoma. For all samples, any adrenal gland showing involvement in the tumor lesion was excluded
upon histological examination. All patients gave their written informed consent for the use of samples
and clinical data, and the protocol of the study was approved by our local ethics committee, (Comitato
etico interaziendale A.O.U. Città della Salute e della Scienza di Torino), Project ID CEI/28, date of
approval 14 May 2007).
4.2. DNA Sequencing for KCNJ5, ATP1A1, ATP2B3, and CACNA1D
DNA fragments from KCNJ5, ATP1A1, ATP2B3, and CACNA1D were amplified by PCR as
previously reported [28,29]. The validity of novel mutations was confirmed by sequencing both
strands of an independently amplified PCR fragment. Of the presented cohort of adrenal samples,
36 were included in the study by Fernandes-Rosa et al. [29]. Of the included samples, 16 adrenal
nodules carried a mutation in the KCNJ5 gene, six in the ATP1A1 or ATP2B3 genes, and five in the
CACNA1D gene, while 19 samples had no mutations in any of these genes.
4.3. Pathological Analysis
Histological examination was performed by an experienced pathologist (I.C.). All adrenal
glands included in the study were embedded in paraffin, cut into 3-µm-thick slices, and stained
with hematoxylin and eosin (H&E). After accurate macroscopical and microscopical analysis, the final
diagnosis of APA was established when a single nodule was present, while the final diagnosis of
unilateral adrenal hyperplasia (UAH) was established in the presence of several nodules of varying
sizes (with or without a dominant one). In the case of UAH, the dominant nodule was used for
gene-expression studies, provided that it was the one identified with CYP11B2 expression upon
immunohistochemistry analysis.
After examination for the known features of ZF (large, lipid-laden clear cells with round to oval
vesicular nuclei), ZG (small, compact cells with a high nuclear/cytoplasmic ratio, and a moderate
amount of lipids), and zona reticularis (lipid-sparse cytoplasm, and compact cells) cells [20,30],
the tumors were categorized as ZF-like when the percentage of large vacuolated cells was greater
than 50%, and ZG-type when the percentage of ZF-like cells was ≤50% and the ZG-like cells were
the prevalent cell type. Of the analyzed samples, 36 were previously included in the study by
Monticone et al. [31].
The final histopathological diagnosis was APA in 35 cases, and multinodular hyperplasia in
11 cases. Twenty-five samples (23 APA samples and two UAH samples) were composed mainly
of ZG-like cells, and 21 samples (19 APA samples and 3 UAH samples) were composed mainly of
ZF-like cells.
4.4. Immunohistochemistry Analyses
Immunohistochemistry analysis was performed using the following primary antibodies: CYP11B2
(CYP11B2-41-17) [32], HSD3B1 (Abnova), HSD3B2 (KALKG619) [13], Cry1 (Abgent), and Cry2 (Abcam),
as detailed in Table S2.
Formalin-fixed paraffin-embedded tumor samples were cut into sequential 2-µm-thick sections,
and deparaffinized and stained at the Pathology Department using a fully automated Ventana
BenchMark ULTRA stainer (Ventana, Tucson, AZ, USA), according to the manufacturers’ instructions.
Binding of peroxidase-coupled antibodies was detected using the ultraView Universal DAB Detection
Kit as a substrate, and the sections were counterstained with hematoxylin.
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4.5. Cell Culture and Transfection
HAC15 adrenocortical cells were cultured as previously reported [33]. For experiments, cells were
plated at a density of 4 × 105 cells/well in a 12-well plate for 48 h. After overnight incubation in
low-serum medium (DMEM/F-12 containing 0.1% cosmic calf serum, and antibiotics), cells were
stimulated with 100 nM AngII (reference value in normotensive individuals 24 ± 17 pM [34])
(Sigma #A9525) ± 1 µM irbesartan (Sigma #I2286) or forskolin (10 µM, Sigma #F6886) for 6, 12,
and 24 h, and then harvested for RNA extraction, and gene-expression studies.
CRY1 and CRY2 gene silencing was performed using the Amaxa technology (Program X-005).
One million cells were electroporated in 100 µL of Nucleofector solution R, using 2 µL of a 100-µmol/L
solution of Silencer Select predesigned small interfering RNA (siRNA) (Thermo Fisher Scientific,
Waltham, MA, USA). After electroporation, cells were plated in a six-well plate, and recovered for
24 h. The medium was then changed to experimental low-serum medium (0.1% cosmic calf serum),
and the cells were starved overnight. The following morning, cells were harvested for RNA extraction,
and gene-expression studies.
4.6. RNA Extraction, and Gene-Expression Studies
RNA isolation from adrenal tissue and cultured cells, and subsequent reverse transcription
were both performed as previously reported [33]. Real-time PCR was performed in triplicate using
TaqMan gene-expression assays (Thermo Scientific) for CRY1, CRY2, HSD3B1, HSD3B2, PER1, NR4A2,
and CYP11B2. Gene-expression levels were analyzed using the 2−∆∆Ct relative quantification method,
using 18S RNA or GAPDH as endogenous reference genes.
4.7. Statistical Analyses
IBM SPSS statistics v. 24 was used for the statistical analysis. Data were expressed as mean
± standard deviation or median [25◦–75◦]. Differences between variables were evaluated using
one-way ANOVA followed by Bonferroni’s or Dunnett’s post-hoc tests, when appropriate, and paired
(to compare the expression between the adrenal nodule and the corresponding adjacent adrenal
cortex) or unpaired t-tests or Mann–Whitney tests. A probability of less than 0.05 was considered as
statistically significant.
5. Conclusions
Our results supported the hypothesis that CRY1 and CRY2, being AngII-regulated genes,
and showing a differential expression in APAs when compared with the adjacent adrenal cortex,
might be involved in adrenal cell function, and in the regulation of aldosterone production.
However, silencing CRY1 and CRY2 expression in HAC15 adrenocortical cells resulted only in a modest
upregulation of the HSD3B2 gene, which was not consistent with the experimental observations in
the Cry-null animal model. Species differences should be considered when studying the role of these
genes in adrenal function, and further exploration in this research area is warranted to elucidate the
complex role of the circadian clock in adrenal aldosterone production.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/6/
1675/s1.
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